抗癌药-话题@MedSci

#抗癌药#

351篇内容 | 5647人围观

关注话题

话题活跃用户

#插入话题

插入图片

最新最热

[GetTopicListResponse(id=1314666, encodeId=6acd13146664f, content=<a href='/topic/show?id=9d4b5554131' target=_blank style='color:#2F92EE;'>#抗癌药#</a>, objectTitle=诺华抗癌药Jakavi达真性红细胞增多症III期临床主要终点, objectType=article, longId=71290, objectId=e56ee129027, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=e56ee129027, replyNumber=0, likeNumber=47, createdTime=2016-06-22, rootId=0, userName=sunylz, userId=12de429, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=e56ee129027, moduleTitle=诺华抗癌药Jakavi达真性红细胞增多症III期临床主要终点, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=e56ee129027)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1314665, encodeId=f1b4131466545, content=<a href='/topic/show?id=9d4b5554131' target=_blank style='color:#2F92EE;'>#抗癌药#</a>, objectTitle=诺华联合卫材将在美国推出抗癌药Lenvima/Afinitor组合疗法, objectType=article, longId=70375, objectId=c875e0375c6, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=c875e0375c6, replyNumber=0, likeNumber=85, createdTime=2016-06-11, rootId=0, userName=sunylz, userId=12de429, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=c875e0375c6, moduleTitle=诺华联合卫材将在美国推出抗癌药Lenvima/Afinitor组合疗法, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=c875e0375c6)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1314664, encodeId=350d13146641e, content=<a href='/topic/show?id=9d4b5554131' target=_blank style='color:#2F92EE;'>#抗癌药#</a>, objectTitle=ASCO 2016：靶向p53的抗癌药物APR-246临床试验取得成功, objectType=article, longId=70340, objectId=dfa1e034020, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=dfa1e034020, replyNumber=0, likeNumber=75, createdTime=2016-06-11, rootId=0, userName=sunylz, userId=12de429, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=dfa1e034020, moduleTitle=ASCO 2016：靶向p53的抗癌药物APR-246临床试验取得成功, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=dfa1e034020)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1314662, encodeId=5bc7131466252, content=<a href='/topic/show?id=9d4b5554131' target=_blank style='color:#2F92EE;'>#抗癌药#</a>, objectTitle=卫材新型抗癌药HALAVEN获菲律宾批准治疗软组织肉瘤, objectType=article, longId=70028, objectId=4e7ae002861, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=4e7ae002861, replyNumber=0, likeNumber=62, createdTime=2016-06-07, rootId=0, userName=sunylz, userId=12de429, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=4e7ae002861, moduleTitle=卫材新型抗癌药HALAVEN获菲律宾批准治疗软组织肉瘤, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=4e7ae002861)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1314663, encodeId=d327131466389, content=<a href='/topic/show?id=9d4b5554131' target=_blank style='color:#2F92EE;'>#抗癌药#</a>, objectTitle=第5个适应症！欧盟批准艾伯维突破性抗癌药Imbruvica一线治疗慢性淋巴细胞白血病（CLL）, objectType=article, longId=70030, objectId=0f9ae003001, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=0f9ae003001, replyNumber=0, likeNumber=60, createdTime=2016-06-07, rootId=0, userName=sunylz, userId=12de429, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=0f9ae003001, moduleTitle=第5个适应症！欧盟批准艾伯维突破性抗癌药Imbruvica一线治疗慢性淋巴细胞白血病（CLL）, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=0f9ae003001)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1314661, encodeId=ad3913146610c, content=<a href='/topic/show?id=9d4b5554131' target=_blank style='color:#2F92EE;'>#抗癌药#</a>, objectTitle=FDA批的抗癌药，竟有1/3不靠谱！, objectType=article, longId=69899, objectId=606e698999f, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=606e698999f, replyNumber=0, likeNumber=82, createdTime=2016-06-05, rootId=0, userName=sunylz, userId=12de429, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=606e698999f, moduleTitle=FDA批的抗癌药，竟有1/3不靠谱！, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=606e698999f)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1314660, encodeId=42fd1314660bf, content=<a href='/topic/show?id=9d4b5554131' target=_blank style='color:#2F92EE;'>#抗癌药#</a>, objectTitle=欧盟CHMP支持批准武田抗癌药Adcetris用于霍奇金淋巴瘤患者干细胞移植后的巩固治疗, objectType=article, longId=69496, objectId=dae2694960d, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=dae2694960d, replyNumber=0, likeNumber=78, createdTime=2016-06-01, rootId=0, userName=sunylz, userId=12de429, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=dae2694960d, moduleTitle=欧盟CHMP支持批准武田抗癌药Adcetris用于霍奇金淋巴瘤患者干细胞移植后的巩固治疗, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=dae2694960d)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1314659, encodeId=e3061314659f7, content=<a href='/topic/show?id=9d4b5554131' target=_blank style='color:#2F92EE;'>#抗癌药#</a>, objectTitle=阿斯利康抗癌药Faslodex（氟维司群）治疗HR+晚期乳腺癌疗效显著优于Arimidex（阿那曲唑）, objectType=article, longId=69402, objectId=83826940262, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=83826940262, replyNumber=0, likeNumber=53, createdTime=2016-05-30, rootId=0, userName=sunylz, userId=12de429, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=83826940262, moduleTitle=阿斯利康抗癌药Faslodex（氟维司群）治疗HR+晚期乳腺癌疗效显著优于Arimidex（阿那曲唑）, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=83826940262)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1314658, encodeId=42e013146583c, content=<a href='/topic/show?id=9d4b5554131' target=_blank style='color:#2F92EE;'>#抗癌药#</a>, objectTitle=Nature：新一代靶向mTOR抑制剂，1+1>2的“合体”抗癌药, objectType=article, longId=69287, objectId=b78c6928e4d, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=b78c6928e4d, replyNumber=0, likeNumber=69, createdTime=2016-05-28, rootId=0, userName=sunylz, userId=12de429, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=b78c6928e4d, moduleTitle=Nature：新一代靶向mTOR抑制剂，1+1>2的“合体”抗癌药, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=b78c6928e4d)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1314657, encodeId=25d7131465e52, content=<a href='/topic/show?id=9d4b5554131' target=_blank style='color:#2F92EE;'>#抗癌药#</a>, objectTitle=重磅！卫材新型抗癌药Halaven中国乳腺癌III期临床获得成功，上半年向CFDA提交新药申请, objectType=article, longId=68953, objectId=268b6895329, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=268b6895329, replyNumber=0, likeNumber=59, createdTime=2016-05-25, rootId=0, userName=sunylz, userId=12de429, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=268b6895329, moduleTitle=重磅！卫材新型抗癌药Halaven中国乳腺癌III期临床获得成功，上半年向CFDA提交新药申请, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=268b6895329)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1314656, encodeId=6e5f131465608, content=<a href='/topic/show?id=9d4b5554131' target=_blank style='color:#2F92EE;'>#抗癌药#</a>, objectTitle=Cell子刊：为何抗癌药物无法渗透实体瘤？肿瘤内部压力大是重要原因, objectType=article, longId=68402, objectId=c515684026a, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=c515684026a, replyNumber=0, likeNumber=53, createdTime=2016-05-18, rootId=0, userName=sunylz, userId=12de429, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=c515684026a, moduleTitle=Cell子刊：为何抗癌药物无法渗透实体瘤？肿瘤内部压力大是重要原因, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=c515684026a)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1314655, encodeId=e42b1314655ee, content=<a href='/topic/show?id=9d4b5554131' target=_blank style='color:#2F92EE;'>#抗癌药#</a>, objectTitle=消息！拜耳抗癌药Stivarga肝细胞癌III期临床大获成功, objectType=article, longId=67827, objectId=d4666e827af, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=d4666e827af, replyNumber=0, likeNumber=119, createdTime=2016-05-11, rootId=0, userName=sunylz, userId=12de429, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=d4666e827af, moduleTitle=消息！拜耳抗癌药Stivarga肝细胞癌III期临床大获成功, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=d4666e827af)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1314654, encodeId=5ccf131465453, content=<a href='/topic/show?id=9d4b5554131' target=_blank style='color:#2F92EE;'>#抗癌药#</a>, objectTitle=Sciene：抗癌药喜树碱可能用于脓毒症的治疗, objectType=article, longId=67382, objectId=0ff46e38282, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=0ff46e38282, replyNumber=0, likeNumber=63, createdTime=2016-05-03, rootId=0, userName=sunylz, userId=12de429, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=0ff46e38282, moduleTitle=Sciene：抗癌药喜树碱可能用于脓毒症的治疗, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=0ff46e38282)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1314653, encodeId=0c0313146532f, content=<a href='/topic/show?id=9d4b5554131' target=_blank style='color:#2F92EE;'>#抗癌药#</a>, objectTitle=FDA抗癌药专家委员会12：1拒绝提前批准rociletinib, objectType=article, longId=66506, objectId=2526665060b, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=2526665060b, replyNumber=0, likeNumber=23, createdTime=2016-04-15, rootId=0, userName=sunylz, userId=12de429, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=2526665060b, moduleTitle=FDA抗癌药专家委员会12：1拒绝提前批准rociletinib, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=2526665060b)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1314652, encodeId=e9d1131465234, content=<a href='/topic/show?id=9d4b5554131' target=_blank style='color:#2F92EE;'>#抗癌药#</a>, objectTitle=Diabetes：抗癌药物格列卫可治疗2型糖尿病, objectType=article, longId=65708, objectId=4ebd65e084e, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=4ebd65e084e, replyNumber=0, likeNumber=80, createdTime=2016-03-31, rootId=0, userName=sunylz, userId=12de429, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=4ebd65e084e, moduleTitle=Diabetes：抗癌药物格列卫可治疗2型糖尿病, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=4ebd65e084e)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1314651, encodeId=187d13146517b, content=<a href='/topic/show?id=9d4b5554131' target=_blank style='color:#2F92EE;'>#抗癌药#</a>, objectTitle=纳米技术和抗癌药联手治愈乳腺癌, objectType=article, longId=65549, objectId=d5db6554973, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=d5db6554973, replyNumber=0, likeNumber=105, createdTime=2016-03-28, rootId=0, userName=sunylz, userId=12de429, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=d5db6554973, moduleTitle=纳米技术和抗癌药联手治愈乳腺癌, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=d5db6554973)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1314650, encodeId=dcf3131465060, content=<a href='/topic/show?id=9d4b5554131' target=_blank style='color:#2F92EE;'>#抗癌药#</a>, objectTitle=抗癌药物格列卫专利到期患者使用伊马替尼5年可省10万美元, objectType=article, longId=65158, objectId=810765158aa, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=810765158aa, replyNumber=0, likeNumber=71, createdTime=2016-03-23, rootId=0, userName=sunylz, userId=12de429, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=810765158aa, moduleTitle=抗癌药物格列卫专利到期患者使用伊马替尼5年可省10万美元, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=810765158aa)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1314649, encodeId=1d0f1314649c9, content=<a href='/topic/show?id=9d4b5554131' target=_blank style='color:#2F92EE;'>#抗癌药#</a>, objectTitle=生物标志物驱动精准医疗的又一典范：FDA批准辉瑞抗癌药Xalkori治疗ROS1阳性非小细胞肺癌, objectType=article, longId=64856, objectId=125f6485664, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=125f6485664, replyNumber=0, likeNumber=67, createdTime=2016-03-17, rootId=0, userName=sunylz, userId=12de429, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=125f6485664, moduleTitle=生物标志物驱动精准医疗的又一典范：FDA批准辉瑞抗癌药Xalkori治疗ROS1阳性非小细胞肺癌, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=125f6485664)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1314648, encodeId=731b1314648da, content=<a href='/topic/show?id=9d4b5554131' target=_blank style='color:#2F92EE;'>#抗癌药#</a>, objectTitle=5个适应证！FDA批准艾伯维突破性抗癌药Imbruvica一线治疗慢性淋巴细胞白血病（CLL）, objectType=article, longId=64673, objectId=6448646e38c, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=6448646e38c, replyNumber=0, likeNumber=52, createdTime=2016-03-13, rootId=0, userName=sunylz, userId=12de429, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=6448646e38c, moduleTitle=5个适应证！FDA批准艾伯维突破性抗癌药Imbruvica一线治疗慢性淋巴细胞白血病（CLL）, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=6448646e38c)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1314647, encodeId=e5e6131464e8f, content=<a href='/topic/show?id=9d4b5554131' target=_blank style='color:#2F92EE;'>#抗癌药#</a>, objectTitle=美国九家癌症中心起诉基因泰克违约偷减抗癌药赫赛汀剂量, objectType=article, longId=64036, objectId=3f9f64036a0, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=3f9f64036a0, replyNumber=0, likeNumber=55, createdTime=2016-03-04, rootId=0, userName=sunylz, userId=12de429, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=3f9f64036a0, moduleTitle=美国九家癌症中心起诉基因泰克违约偷减抗癌药赫赛汀剂量, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=3f9f64036a0)], followStatus=false, userIsMember=false, type=1, lengthMark=0)] 梅斯话题小助手

抗癌药

2020-05-29

sunylz (审核中...)

前往app查看评论内容

#抗癌药#

诺华抗癌药Jakavi达真性红细胞增多症III期临床主要终点

2016-06-22

sunylz (审核中...)

前往app查看评论内容

#抗癌药#

诺华联合卫材将在美国推出抗癌药Lenvima/Afinitor组合疗法

2016-06-11

sunylz (审核中...)

前往app查看评论内容

#抗癌药#

ASCO 2016：靶向p53的抗癌药物APR-246临床试验取得成功

2016-06-11

sunylz (审核中...)

前往app查看评论内容

#抗癌药#

卫材新型抗癌药HALAVEN获菲律宾批准治疗软组织肉瘤

2016-06-07

sunylz (审核中...)

前往app查看评论内容

#抗癌药#

第5个适应症！欧盟批准艾伯维突破性抗癌药Imbruvica一线治疗慢性淋巴细胞白血病（CLL）

2016-06-07

sunylz (审核中...)

前往app查看评论内容

#抗癌药#

FDA批的抗癌药，竟有1/3不靠谱！

2016-06-05

sunylz (审核中...)

前往app查看评论内容

#抗癌药#

欧盟CHMP支持批准武田抗癌药Adcetris用于霍奇金淋巴瘤患者干细胞移植后的巩固治疗

2016-06-01

sunylz (审核中...)

前往app查看评论内容

#抗癌药#

阿斯利康抗癌药Faslodex（氟维司群）治疗HR+晚期乳腺癌疗效显著优于Arimidex（阿那曲唑）

2016-05-30

sunylz (审核中...)

前往app查看评论内容

#抗癌药#

Nature：新一代靶向mTOR抑制剂，1+1>2的“合体”抗癌药

2016-05-28

sunylz (审核中...)

前往app查看评论内容

#抗癌药#

重磅！卫材新型抗癌药Halaven中国乳腺癌III期临床获得成功，上半年向CFDA提交新药申请

2016-05-25

sunylz (审核中...)

前往app查看评论内容

#抗癌药#

Cell子刊：为何抗癌药物无法渗透实体瘤？肿瘤内部压力大是重要原因

2016-05-18

sunylz (审核中...)

前往app查看评论内容

#抗癌药#

消息！拜耳抗癌药Stivarga肝细胞癌III期临床大获成功

2016-05-11

sunylz (审核中...)

前往app查看评论内容

#抗癌药#

Sciene：抗癌药喜树碱可能用于脓毒症的治疗

2016-05-03

sunylz (审核中...)

前往app查看评论内容

#抗癌药#

FDA抗癌药专家委员会12：1拒绝提前批准rociletinib

2016-04-15

sunylz (审核中...)

前往app查看评论内容

#抗癌药#

Diabetes：抗癌药物格列卫可治疗2型糖尿病

2016-03-31

sunylz (审核中...)

前往app查看评论内容

#抗癌药#

纳米技术和抗癌药联手治愈乳腺癌

2016-03-28

sunylz (审核中...)

前往app查看评论内容

#抗癌药#

抗癌药物格列卫专利到期患者使用伊马替尼5年可省10万美元

2016-03-23

sunylz (审核中...)

前往app查看评论内容

#抗癌药#

生物标志物驱动精准医疗的又一典范：FDA批准辉瑞抗癌药Xalkori治疗ROS1阳性非小细胞肺癌

2016-03-17

sunylz (审核中...)

前往app查看评论内容

#抗癌药#

5个适应证！FDA批准艾伯维突破性抗癌药Imbruvica一线治疗慢性淋巴细胞白血病（CLL）

2016-03-13

sunylz (审核中...)

前往app查看评论内容

#抗癌药#

美国九家癌症中心起诉基因泰克违约偷减抗癌药赫赛汀剂量

2016-03-04

科室
- - 订阅+
  - 更多科室
工具
服务